Preview

Научно-практическая ревматология

Расширенный поиск

ДОНА (ГЛЮКОЗАМИН СУЛЬФАТ) - ПАТОГЕНЕТИЧЕСКИ ОБОСНОВАННОЕ ПРИМЕНЕНИЕ ПРИ ОСТЕОАРТРОЗЕ

https://doi.org/10.14412/1995-4484-2003-767

Список литературы

1. <div><p>Насонова В. А., Халтаев Н. Г. Международное десятилетие болезней костей и суставов (The bone and joint Decade). Тер. архив, 2001, 5, 5-7.</p><p>Насонова В. А. Рациональное применение НПВП в ревматологии. РМЖ. 2002. 10, 6, 302-307.</p><p>Насонов Е. Л. НПВП (перспективы применения в медицине). М, 2000.</p><p>Насонов Е. Л. Современные направления фармакотерапии остеоартроза. Consilium medicum, 2001. 3. 9. 409414.</p><p>Насонов Е. Л., Насонова В. А. Фармакотерпаия боли: взгляд ревматолога. Consilium medicum, 2001, 2, 12, 509-514.</p><p>Цветкова Е. С. Насонов Е. Л., Бадокин В. В. Дона- перспективный препарат для лечения остеоартроза. Российская ревматология, 1999. 5, 34-38.</p><p>Aniin A. R., Abramson S. В. The role of nitric oxide in articular cartilaae breakdown in ostoarthritis. Curr. Opin. Rheumatol., 1998, 10, 263-268.</p><p>American College of Rheumatology Subcommittee on Osteoarthritis Guadelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthr. Rheum. 2000, 43, 1905-1915.</p><p>Bassleer C. Rovati L,, Franchimont P. Stimulation of proteoglycan production by chondroitin sulfates in chondrocytes isolate from human osteoarthritis articular cartilage in vitro. Osteoarthrit. Cartilage. 1998, 6, 427-434.</p><p>Brooks P., Emery P., Evants J. F. et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatol. 1999,38. 779-788.</p><p>Conrozier Т. Mathieu P. Piperno M. et al. Glucosamin sulfate significantly reduced cartilage destruction in a rabbit model of osteoarthrotis. Arthr. Rheum.,1998, 41, 147.</p><p>Cremer P. Hochberg М. C. Osteoarthritis. Lancet. 1997, 350. 503-508.</p><p>Dodge G. R., Hawkins D. F„ Jienez S. A. Modulation of agggrecan, MM PI, and MMP3 production by glucosamin sulfate in cultured human osteoarthritic articular chondrocytes labstract]. Arthr. Rheum., 1999, 42 (suppl), S253.</p><p>DuBois R.N., Abramson S.B., Crofford L. et al. Cyclooxygenase in biology and medicine. FASEB J. 1998, 12, 1063-1073.</p><p>Felson D. Т. Lawrence R. C., Dieppa P. A. et al. Osteoarthritis: new insights, part 16 the disease and its risk factors. Ann. Intern. Med. 2000, 133, 635-646.</p><p>Gouze J. N. Bodji K„ Gulberti S. et al. Interleukin -1 down-regulates the expression ofglucuronosulflransferase I. a key enzyme priming glycosaminoglican biosynthesis: influence of glucosamine on interleukin -I -mediated effects in rat chondrocytes. Arthr. Rheum., 2001, 44, 351 - 360.</p><p>Me Alindon Т. E., La Valley M. P., Gulin J. P. et al. Glucosamin and chondroitin for the treatment of osteoarthritis. A systematic qualify assessment and metaanalysis. JAMA. 2000, 283, 1469-1475.</p><p>Me Alindon Т. E. Glucosamine for osteoarthritis: dawn of a new era? Lancet. 2001. 357, 247-248.</p><p>Muller-Fassbender H., Bach G. L., Haase W. et al. Glucosamin sulfate compered to ibuprofen in osteoarthritis of the knee. Osteoarthrit. Cartilage, 1994, 2, 61-69.</p><p>Noack W. Fischer М., Forster К. K. et al. Glucosamin sul- fat in osteoarthritis of the knee. Osteoarthrit. Cartilage. 1994, 2. 51-59.</p><p>Noyszewski E. A., Wroblewski K., Dodge G. R. et al.Preferentioal incorporation of glucosamin moieties of chondroitin sulfates in articular cartilage explants. Arthr. Rheum., 2001, 44. 1089-1095.</p><p>Osteoarthritis. Brandt K. D., Doherty М., Lohmander L. S. ed Oxford Univ Press. I99S.</p><p>Pavelka K, Gatterova S, Olejarova M. et al. Glucosamin sulfate and delav of progression of knee osteoarthritis. Arch. Intern. Med. 2002. 162. 2113-2123.</p><p>Pelleter J. P. Martel-Pelletier J., Howell D. S. In: Koopmen ed. Arthritis and Allied Conditions. Textbook of Rheumatology. Williams &amp; Wikins. Baltimore. 1993, 2, 1969-1984.</p><p>Piperno М., Reboul P., Hellio L. et al. Glucosamin sulfate modulates dysregulated functions of humen osteoarthritic chondrocytes in vitro. Osteoarthrit. Cartilage., 2000, 8, 207212.</p><p>Piperno М. Reboul P. Hellio L. et al.Osteoarthritis cartilage fibrillation is associated with a decrease in chodrocyte adgesion to fibronectin. Osteoarthrit. Cartilage. 1998, 6, 393-399.</p><p>Reginster J. Y, Deroisy R. Paul I. et al. Long-term effects of glucosamin sulphat on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet, 2001, 357, 251-256.</p><p>Reichclt A. Foster К. K., Ficher M. et ul. efficacy and safety in intramusculer glucosamin sulfat in osteoarthritis of the knee. Aiv.neim-Forsch/Drug Research. 1994, 44, 75-80.</p><p>Rovati L. C. The clinical profile of glucosaminc sulfat as a selective symptom modifying drug in osteoarthritis: current data and perspectives [abstract!, Osteoarthrit. Cartilage, 1997, S(suppl), 72.</p><p>Sundy J. D., Gamett D., Thompson V. et al. Chondrocyte- mediated catabolism of aggrecan: aggreganase-dependent clevage induced by interleukin-1 or retinoic acid can be inhibited by glucosamin. Biochem. J., 1998, 335, 59-66.</p><p>Setnikar I., Cereda R., Pacini A. et al. Antircactive Properties of glucosamine sulfate. Arzneim-Forsch/Drug Research. 1991. 4, 2. 157-161.</p><p>Setnikar I.,Giachetti C., Zanolo G. et al. Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14 C] glucosamin to the rat. Pharmacotherap. 1984, 3, 538-550.</p><p>Setnikar f.Giachetti C., Zanolo G. et al. Pharmacokinetics of glucosamine in the dog and man. Arzneim-Forsch/Drug Research., 1986, 36, 729-735.</p><p>Setnikar I., Rovari L. C. Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittelforschung., 2001, 51, 699-725.</p><p>Smith CJ. Zhang Y. Kobold C.M. et al. Pharmacological analys of cyclooxigenase-1 in inflammation. Proc. Nat. Acad. Sci., 1998. 95, I3I3-I3IS.</p><p>Towheed Т. E. Anastassiades T. S. Glucosamin and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA, 2000, 283, 14831484.</p><p>Wolfe F., Zhao S., Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. Arthr. Rheum., 2000, 43, 378-385.</p><p>Whelton A., Fort J. J., Puma J. A. et al. Cyclooxigenase-2- specific inhibitors and cardiorenal function: a randomized? Controlled trial of ceiecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther., 2001, 8, 85-96.</p><p>Yaron I., Shirazi I., Judovich R. et al. Glucosamin sulfate ingibits nitric oxide and stromelysin production in cartilage cultures and reverses IL-1 inhibition of osteoarthritis articular cartilage syntesis [abstract]. Ann. Rheum. Dis., 2001, 60 (suppl), 50.</p></div><br />


Рецензия

Для цитирования:


Tsvetkova E.S., Ionichonok N.G. ДОНА (ГЛЮКОЗАМИН СУЛЬФАТ) - ПАТОГЕНЕТИЧЕСКИ ОБОСНОВАННОЕ ПРИМЕНЕНИЕ ПРИ ОСТЕОАРТРОЗЕ. Научно-практическая ревматология. 2003;41(2):35-37. https://doi.org/10.14412/1995-4484-2003-767

For citation:


Tsvetkova E.S., Ionichonok N.G. DONA (glucosamin sulfate) - pathogeneticaly proved application in osteoarthritis. Rheumatology Science and Practice. 2003;41(2):35-37. (In Russ.) https://doi.org/10.14412/1995-4484-2003-767

Просмотров: 697


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)